BAJAJ BROKING

open-demat-imgOpen Demat
be-a-partner-imgBe a Partner
samadhan-imgSamadhan
InstallInstall App
Download AppInstall App
Notification close image
No new Notification messages
card image
Seshaasai Technologies Ltd IPO
Apply for the Seshaasai Technologies Ltd IPO through UPI in Just minutes
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

11394

0

ZOTA

img img img img
Compare to down-arrow
View down-arrow
Display down-arrow
Studies down-arrow
No Data Available

ZOTA HEALTH CARE LIMITED performance

Today’s low

Today’s high

₹ 1629.00 ₹ 1680.00
₹ 1670.20

52 week low

52 week high

₹ 632.65 ₹ 1740.00
₹ 1670.20

Open Price

₹ 1629.00

Prev. Close

₹ 1628.90

Volume (Shares)

62301.00

Total traded value

₹ 1040.55

Upper Circuit

₹ 1954.60

Lower Circuit

₹ 1303.20

info

ZOTA HEALTH CARE LIMITED Share Price Update

As of the latest trading session, ZOTA HEALTH CARE LIMITED share price is currently at ₹ 1670.2, which is up by ₹ 41.29 from its previous closing. Today, the stock has fluctuated between ₹ 1629.00 and ₹ 1680.00. Over the past year, ZOTA HEALTH CARE LIMITED has achieved a return of 151.99 %. In the last month alone, the return has been 8.98 %. Read More...

Investment Returns

Over 1 Month [-]% Over 3 Months [-]% Over 6 Months [-]% Over 1 Year [-]%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

ZOTA HEALTH CARE LIMITED fundamentals


  • Market cap (Cr)

    5,118.10

  • P/E Ratio (TTM)

    249.66

  • Beta

    1.14

  • Book Value / share

    148.75

  • Return on equity

    3.93%

  • EPS (TTM)

    6.69

  • Dividend yield

    0.06%

  • Net profit/quarter (Cr)

    9.91

info icon alternate text

  • Market cap (Cr)

    [-]

  • P/E Ratio (TTM)

    [-]

  • Beta

    [-]

  • Book Value / share

    [-]

  • Return on equity

    [-]%

  • EPS (TTM)

    [-]

  • Dividend yield

    0.06%

  • Net profit/quarter (Cr)

    [-]

info icon alternate text

ZOTA HEALTH CARE LIMITED Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars SEP 2025 (Values in Cr)
Revenue 99.42
Operating Expense 89.62
Net Profit 9.91
Net Profit Margin (%) 9.96
Earnings Per Share (EPS) 3.27
EBITDA 14.07
Effective Tax Rate (%) 24.17
Particulars JUN 2025 (Values in Cr)
Revenue 78.01
Operating Expense 71.70
Net Profit 5.90
Net Profit Margin (%) 7.56
Earnings Per Share (EPS) 2.03
EBITDA 9.39
Effective Tax Rate (%) 30.87
Particulars MAR 2025 (Values in Cr)
Revenue 77.93
Operating Expense 75.01
Net Profit 2.60
Net Profit Margin (%) 3.33
Earnings Per Share (EPS) 0.92
EBITDA 5.43
Effective Tax Rate (%) 41.17
Particulars DEC 2024 (Values in Cr)
Revenue 68.13
Operating Expense 67.68
Net Profit 2.08
Net Profit Margin (%) 3.05
Earnings Per Share (EPS) 0.76
EBITDA 3.00
Effective Tax Rate (%) 2.80
Particulars SEP 2024 (Values in Cr)
Revenue 59.01
Operating Expense 57.02
Net Profit 2.35
Net Profit Margin (%) 3.98
Earnings Per Share (EPS) 0.89
EBITDA 4.21
Effective Tax Rate (%) 20.60
Particulars MAR 2025 (Values in Cr)
Revenue 257.28
Operating Expense 250.06
Net Profit 8.62
Net Profit Margin (%) 3.35
Earnings Per Share (EPS) 3.16
EBITDA 16.07
Effective Tax Rate (%) 27.28
Particulars MAR 2024 (Values in Cr)
Revenue 166.59
Operating Expense 163.73
Net Profit 3.38
Net Profit Margin (%) 2.02
Earnings Per Share (EPS) 1.32
EBITDA 8.28
Effective Tax Rate (%) 31.16
Particulars MAR 2023 (Values in Cr)
Revenue 138.37
Operating Expense 132.84
Net Profit 6.59
Net Profit Margin (%) 4.76
Earnings Per Share (EPS) 2.62
EBITDA 11.10
Effective Tax Rate (%) 23.54
Particulars MAR 2022 (Values in Cr)
Revenue 131.53
Operating Expense 118.97
Net Profit 10.58
Net Profit Margin (%) 8.04
Earnings Per Share (EPS) 4.25
EBITDA 16.99
Effective Tax Rate (%) 25.44
Particulars MAR 2021 (Values in Cr)
Revenue 106.84
Operating Expense 109.44
Net Profit -0.16
Net Profit Margin (%) -0.14
Earnings Per Share (EPS) -0.07
EBITDA 2.96
Effective Tax Rate (%) 46.87
Particulars MAR 2025 (Values in Cr)
Book Value / Share 78.12
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.75
EBITDA Margin -1.25
Particulars MAR 2024 (Values in Cr)
Book Value / Share 34.81
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.82
EBITDA Margin 4.83
Particulars MAR 2023 (Values in Cr)
Book Value / Share 31.94
ROE % -7.42
ROCE % -2.30
Total Debt to Total Equity 0.35
EBITDA Margin 6.64
Particulars MAR 2022 (Values in Cr)
Book Value / Share 35.62
ROE % 11.43
ROCE % 14.77
Total Debt to Total Equity 0.10
EBITDA Margin 12.52
Particulars MAR 2021 (Values in Cr)
Book Value / Share 26.99
ROE % -1.70
ROCE % -1.88
Total Debt to Total Equity 0.00
EBITDA Margin 1.76
Particulars MAR 2025 (Values in Cr)
Book Value / Share 110.83
ROE % 3.93
ROCE % 5.65
Total Debt to Total Equity 0.03
EBITDA Margin 6.25
Particulars MAR 2024 (Values in Cr)
Book Value / Share 47.11
ROE % 3.13
ROCE % 4.52
Total Debt to Total Equity 0.07
EBITDA Margin 4.96
Particulars MAR 2023 (Values in Cr)
Book Value / Share 37.54
ROE % 7.09
ROCE % 9.24
Total Debt to Total Equity 0.00
EBITDA Margin 8.02
Particulars MAR 2022 (Values in Cr)
Book Value / Share 36.32
ROE % 13.41
ROCE % 17.86
Total Debt to Total Equity 0.00
EBITDA Margin 12.92
Particulars MAR 2021 (Values in Cr)
Book Value / Share 27.02
ROE % -1.63
ROCE % -1.80
Total Debt to Total Equity 0.00
EBITDA Margin 1.81
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 3.61
Total Assets 439.14
Total Liabilities 439.14
Total Equity 227.15
Share Outstanding 28635033
Price to Book Ratio 7.27
Return on Assets (%) -12.84
Return on Capital (%) -24.23
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 1.00
Total Assets 228.32
Total Liabilities 228.32
Total Equity 89.97
Share Outstanding 25847327
Price to Book Ratio 10.07
Return on Assets (%) -6.28
Return on Capital (%) -13.71
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 1.11
Total Assets 158.11
Total Liabilities 158.11
Total Equity 80.35
Share Outstanding 25160327
Price to Book Ratio 7.51
Return on Assets (%) -3.65
Return on Capital (%) -7.18
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2.29
Total Assets 139.09
Total Liabilities 139.09
Total Equity 89.62
Share Outstanding 25160327
Price to Book Ratio 8.19
Return on Assets (%) 6.40
Return on Capital (%) 9.94
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1.34
Total Assets 85.46
Total Liabilities 85.46
Total Equity 66.29
Share Outstanding 24560327
Price to Book Ratio 5.13
Return on Assets (%) -0.24
Return on Capital (%) -0.32
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 1.34
Total Assets 379.72
Total Liabilities 379.72
Total Equity 317.36
Share Outstanding 28635033
Price to Book Ratio 7.27
Return on Assets (%) 2.26
Return on Capital (%) 2.71
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 0.14
Total Assets 173.28
Total Liabilities 173.28
Total Equity 121.77
Share Outstanding 25847327
Price to Book Ratio 10.07
Return on Assets (%) 1.95
Return on Capital (%) 2.48
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 0.87
Total Assets 124.63
Total Liabilities 124.63
Total Equity 94.46
Share Outstanding 25160327
Price to Book Ratio 7.51
Return on Assets (%) 5.29
Return on Capital (%) 6.98
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2.19
Total Assets 125.27
Total Liabilities 125.27
Total Equity 91.37
Share Outstanding 25160327
Price to Book Ratio 8.19
Return on Assets (%) 8.44
Return on Capital (%) 11.58
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1.32
Total Assets 85.51
Total Liabilities 85.51
Total Equity 66.37
Share Outstanding 24560327
Price to Book Ratio 5.13
Return on Assets (%) -0.18
Return on Capital (%) -0.24
Particulars MAR 2025 (Values in Cr)
Net Income -57.64
Cash from Operations -46.48
Cash from Investing -92.18
Cash from Financing 144.76
Net change in Cash 2.61
Free Cash Flow -0.50
Particulars MAR 2024 (Values in Cr)
Net Income -16.16
Cash from Operations -4.45
Cash from Investing -12.90
Cash from Financing 18.77
Net change in Cash -0.11
Free Cash Flow 12.25
Particulars MAR 2023 (Values in Cr)
Net Income -4.69
Cash from Operations 0.13
Cash from Investing 14.70
Cash from Financing -13.88
Net change in Cash -1.18
Free Cash Flow 12.63
Particulars MAR 2022 (Values in Cr)
Net Income 12.43
Cash from Operations 17.06
Cash from Investing -26.65
Cash from Financing 14.27
Net change in Cash 0.95
Free Cash Flow 20.31
Particulars MAR 2021 (Values in Cr)
Net Income -0.36
Cash from Operations -0.82
Cash from Investing 3.82
Cash from Financing -2.41
Net change in Cash 0.51
Free Cash Flow 1.10
Particulars MAR 2025 (Values in Cr)
Net Income 11.84
Cash from Operations -18.80
Cash from Investing -147.84
Cash from Financing 171.26
Net change in Cash 1.20
Free Cash Flow -14.55
Particulars MAR 2024 (Values in Cr)
Net Income 4.90
Cash from Operations -28.62
Cash from Investing -8.66
Cash from Financing 38.07
Net change in Cash -0.73
Free Cash Flow -23.32
Particulars MAR 2023 (Values in Cr)
Net Income 8.62
Cash from Operations -8.15
Cash from Investing 12.75
Cash from Financing -3.78
Net change in Cash -1.32
Free Cash Flow -3.14
Particulars MAR 2022 (Values in Cr)
Net Income 14.19
Cash from Operations 17.39
Cash from Investing -27.05
Cash from Financing 14.27
Net change in Cash 0.87
Free Cash Flow 18.65
Particulars MAR 2021 (Values in Cr)
Net Income -0.31
Cash from Operations -0.77
Cash from Investing 3.90
Cash from Financing -2.46
Net change in Cash 0.59
Free Cash Flow 1.06
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 28.97 14.20 1.50 222.01 25.97 / 67.90
BLISS GVS PHARMA LTD 144.15 13.91 1.34 1524.95 105.05 / 190.65
CIPLA LTD 1517.20 22.52 3.72 122555.05 1310.05 / 1672.20
FERMENTA BIOTECH LIMITED 340.35 8.94 2.56 1001.68 219.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 28.97 23.55 4.03 222.01 25.97 / 67.90
AMRUTAJAN HEALTH LTD 689.65 35.17 5.82 1993.82 548.05 / 829.00
ASTRAZENECA PHARMA IND LT 9138.35 98.83 28.59 22845.88 6301.00 / 10653.05
BLISS GVS PHARMA LTD 144.15 19.45 1.38 1524.95 105.05 / 190.65

ZOTA HEALTH CARE LIMITED shareholding pattern

Holding

40.64%
55.81%
3.48%
0.05%
0.26%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

Transparent Pricing and 360° Services

Choose a Plan That Suits Your Goals and Needs

greenshadow greenshadow redshadow pricing-pack Freedom Pack
₹20/order 14.99% p.a. MTF
tick Stock Picks by Research Analysts tick Seamless Onboarding

Subscription Charge : FREE

greenshadow greenshadow redshadow pricing-pack

Professional Pack
₹10/order 11.99% p.a. MTF
tick Stock Picks by Research Analysts tick Seamless Onboarding

Subscription Charge : ₹2,500 Yearly

50% Brokerage Savings
greenshadow greenshadow redshadow pricing-pack

Signature
0.2% on Delivery 11.99% p.a. MTF
tick Dedicated Relationship Manager tick Customised Brokerage Support tick Stock Picks by Research Analysts tick Experienced Dealer Support

ZOTA HEALTH CARE LIMITED Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
1670.20 2.53 redarrow
red-green-graph indicator
11 Bearish
5 Bullish
  • 5 Days 1624.30
  • 26 Days 1588.70
  • 10 Days 1610.50
  • 50 Days 1546.10
  • 12 Days 1607.40
  • 100 Days 1436.80
  • 20 Days 1596.90
  • 200 Days 1253.20
1599.97 PIVOT

First Support

1564.93

First Resistance

1663.93

Second Support

1500.97

Second Resistance

1698.97

Third Support

1465.93

Third Resistance

1762.93

RSI

61.73

ADX

19.37

MACD

18.68

Williams % R

-11.25

Commodity Channel Index (CCI)

112.76

Date

2025-12-12

Week

28643.00

Same Day

36875.00

Month

35516.00

1 Year

1.15

3 Year

0.92

Over 1 Month

8.98%

down

Over 1 Year

151.99%

down

Over 3 Months

9.70%

down

Over 3 Years

83.78%

down

Over 6 Months

68.34%

down

Over 5 Years

61.73%

down

ZOTA HEALTH CARE LIMITED Corporate Actions

Dividend date Dividend amount Dividend type Record date Instrument type
22 Sep 2025 1.0 Final 22 Sep 2025 Equity shares
20 Sep 2024 1.0 Final 21 Sep 2024 Equity shares
22 Sep 2023 1.0 Final 23 Sep 2023 Equity shares
19 Sep 2022 1.5 Final 21 Sep 2022 Equity shares
22 Sep 2021 1.0 Final 24 Sep 2021 Equity shares
17 Sep 2020 1.0 Final 19 Sep 2020 Equity shares
12 Sep 2019 1.0 Final 14 Sep 2019 Equity shares
02 Aug 2018 3.0 Final 04 Aug 2018 Equity shares
Ex-Date Ex-Bonus Ratio
26 Jul 2019 25 Jul 2019 4:10

ZOTA HEALTH CARE LIMITED Share Price

Zota Health Care Limited is a renowned pharmaceutical company that manufactures, markets, and exports pharmaceutical, ayurvedic, nutraceutical, and over-the-counter (OTC) products. The Company was incorporated in July 12, 2000 and is based out of Surat, Gujarat. The Company meets the requirements of millions of people by increasing access to high-quality, affordable medicines for chronic illnesses including heart disease, diabetes, thyroid disease, and others, giving India's pharmaceutical industry a boost.

The Company has three business verticals: Marketing-a traditional business vertical, and driving business verticals - Exports and Retail harmacy Chain. Through its chain, Davaindia, the largest private-sector generic pharmacy chain, the Company is making strong inroads into the generic retail pharmacy business. The Company's state-of-the-art manufacturing facility at Sachin SEZ serves customers in more than 30 countries. Davaindia is a retail generic pharmacy chain whose core value proposition is providing quality generic medicines at substantial discounts, i.e. 30% to 90%, to their branded equivalents. Davaindia focuses on private-label products in the medicinal, OTC, and ayurvedic categories, with a greater emphasis on chronic therapies and ailments.

The Marketing business vertical involves the direct distribution of generic drugs, OTC products, and other pharmaceutical products through the Company's distribution network across India. In domestic Marketing business, the Company procures finished dosage forms (FDFs) from domestic formulation manufactures and then market them under its portfolio of brands. It has a set of manufacturing partners recognized by the WHO with a rigorous focus on product quality. With a portfolio of more than 3000 products in various categories, such as generics, OTC products, allopathic, ayurvedic, etcetera, the Company cater to a variety of ailments. Currently, the Company has over 1050 distributors spread around the country. Instead of the Company directly engaging in sales, distribution, and promotion activities, its distributors engage in ethical marketing or other sales, distribution, and promotion activities on their own. Instead, it provide distributors directly with incentives to help them sell products more effectively.

Secondly, the exports business vertical started in 2010, following the establishment of formulations manufacturing facility in the Sachin SEZ. The Company is required to export products from this unit in accordance with the laws governing this SEZ. At present, it has product approvals in 30 countries, particularly in the semi-regulated and regulated markets in the African, Asian, CIS, and Latin American countries. In this facility, the Company make around 250 formulations for direct exports and contract manufacturing. . At present, the Company has 253 dossiers approved across multiple countries, and another 311 dossiers have been filed and are pending approval. It significantly increased efforts and investments towards product registration, the results of which are now apparent in the form of product approvals and expansion of export operations.

In the Retail Pharmacy Chain business vertical, the Company operates a chain of pharmacy stores under the brand - 'Davaindia'. Davaindia focuses only on private-label products in the medicinal, OTC, and ayurvedic categories, with a greater emphasis on chronic therapies and ailments. This concept started with three pilot stores in 2017 and has been scaled up to become the largest private-sector generic pharmacy chain with more than 591 stores as of March 2021. Davaindia operates on a unique asset-light franchise model for majority stores. These stores are engaged in exclusive sales of Davaindia products, with more than 95% of products being private-label.

In all areas and media, such as TV commercials, printing, digital & social media, radio, among others, the Company has undertaken bold and aggressive marketing and promotion activities with the firm intention of creating top-of-the-mind brand recall for Davaindia. Davaindia - being a front-runner in private sector generic pharmacy assumed the responsibility to create awareness, propagate virtues and debunk misconceptions about generic drugs.

The Company launched the initial public offer of 46,80,000 equity shares of face value of Rs 10 each, by raising capital of Rs 58.5 Crore , comprising a fresh issue of 31,80,000 equity shares amounting to Rs 39.75 Cr and the offer for sale of 3,60,000 equity shares amounting to Rs 18.75 Cr in May, 2017.

In 2019, the Company opened ~150 Davaindia outlets. Davaindia expanded to over 250 outlets, becoming the fastest-growing private
sector generic pharmacy chain in India in 2020.

The Company acquired a 56% stake in Everyday Herbal Group, licensed by the Khadi and Village Industries Commission of India in May, 2024. The Davaindia footprint expanded the count to 1,582 operational stores in 2025.

Parent organization Indian Private
NSE symbol ZOTA
Founded 2000
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow

Ketankumar Zota

Chairman & Non Executive Director

Moxesh Zota

Managing Director

Kamlesh Zota

Whole-time Director

Himanshu Zota

Whole-time Director

Manukant Zota

Whole-time Director

Varsaben Mehta

Independent Director

Ashvin Variya

Company Secretary

Bhumi Maulik Doshi

Additional Independent Director

Dhiren Prafulbhai Shah

Independent Director

Jayshreeben N Mehta

Independent Director

Right Arrow

Similar stocks

Left Arrow
similar-logo SUNPHARMA
-0.75%
1793.5 -13.69
down-arrow
similar-logo DIVISLAB
-0.05%
6426.5 -3.50
down-arrow
similar-logo TORNTPHARM
-0.57%
3777 -22.00
down-arrow
similar-logo CIPLA
0.33%
1517.4 5.09
down-arrow
similar-logo DRREDDY
0.45%
1279.3 5.80
down-arrow
similar-logo LUPIN
1.54%
2113.9 32.09
down-arrow
similar-logo ZYDUSLIFE
0.71%
929.15 6.60
down-arrow
similar-logo MANKIND
0.55%
2178.8 12.00
down-arrow
similar-logo AUROPHARMA
1.95%
1195.1 22.90
down-arrow
similar-logo ALKEM
-0.20%
5614.5 -11.50
down-arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Zota Health Care Ltd?

Answer Field

Zota Health Care Ltd share price is for NSE ₹ 1,670.20 & for BSE ₹ 0.00 as on Dec 12 2025 03:30 PM.

What is the Market Cap of Zota Health Care Ltd Share?

Answer Field

The market cap of Zota Health Care Ltd for NSE ₹ 4,782.62 & for BSE ₹ 0.00 as on Dec 12 2025 03:30 PM.

What is the 52 Week High and Low of Zota Health Care Ltd?

Answer Field

The 52 Week High and Low of Zota Health Care Ltd for NSE is ₹ 1,740.00 and ₹ 632.65 and for BSE is ₹ 0.00 and ₹ 0.00.

What is 1 year return for Zota Health Care Ltd?

Answer Field

The 1 year returns on the stock has been 151.99%.

What is the P/E Ratio of Zota Health Care Ltd Share?

Answer Field

As on Dec 12 2025 03:30 PM the price-to-earnings (PE) ratio for Zota Health Care Ltd share is 249.66.

What is the PB ratio of Zota Health Care Ltd Share?

Answer Field

As on Dec 12 2025 03:30 PM, the price-to-book (PB) ratio for Zota Health Care Ltd share is 148.75.

How to Buy Zota Health Care Ltd Share?

Answer Field

You can trade in Zota Health Care Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Zota Health Care Ltd Share on Bajaj Broking App?

Answer Field

To buy Zota Health Care Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Zota Health Care Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59

Products

arrow

Calculator

arrow

Platforms

arrow

Mutual Funds & SIP

arrow

Important Links

arrow

Explore

arrow

Corporate

arrow

Discover

arrow

Popular Stocks

arrow

Indian Indices

arrow

Global Indices

arrow

Sector Wise Stocks

arrow

IPO

arrow

Useful Links

footer content

ATTENTION INVESTORS:

“Investments in securities market are subject to market risk, read all the scheme related documents carefully before investing."

"Prevent Unauthorized transactions in your Trading/Demat Account. Update your mobile numbers/email IDs with your stock brokers/Depository Participant. Receive alerts/information of your transaction/all debit and other important transactions in your Trading/ Demat Account directly from Exchange/CDSL/NSDL at the end of the day. Issued in the interest of investors."

" We collect, retain, and use your contact information for legitimate business purposes only, to contact you and to provide you information & latest updates regarding our products & services."  

"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."

"We understand that certain investment advisors may be approaching members of the public including our clients, representing that they are our partners, or representing that their investment advice is based on our research. Please note that we have not engaged any third parties to render any investment advisory services on our behalf nor are we providing any stock recommendations/tips/research report/advisory. Persons making investments on the basis of such advice may lose all or a part of their investments along with the fee paid to such unscrupulous persons. Please be cautious about any phone call that you may receive from persons representing to be such investment advisors, or a part of research firm offering advice on securities. Do not make payments through e-mail links, WhatsApp or SMS. Please do not share your personal or financial information with any person without proper verification. Always trade through a registered broker."

Bajaj Financial Securities Limited is a subsidiary of Bajaj Finance Limited and is a corporate trading and clearing member of BSE Ltd. and National Stock Exchange of India Ltd. (NSEIL), and also a Depository participant with National Securities Depository Ltd (“NSDL”) and Central Depository Services Ltd. (“CDSL”).

Bajaj Financial Securities Limited is engaged in the business of Stock Broking and as a Depository Participant.Bajaj Financial Securities Limited does not provide any advisory services to its clients. Bajaj Financial Securities Limited may share updates from time to time (through various electronic communication modes) which are sourced from public domain and the same are NOT to be construed as any advice or recommendation from Bajaj Financial Securities Limited. Client is requested to independently evaluate and/or consult their professional advisors before arriving at any conclusion to make any investment. The decision to invest shall be the sole responsibility of the Client and shall not hold Bajaj Financial Securities Limited, its employees and associates responsible for any losses, damages of any type whatsoever.

BSE Ltd. is not in any manner answerable, responsible or liable to any person or persons for any acts of omission or commission, errors, mistakes and/or violation, actual or perceived, by us or our partners, agents, associates etc., of any of the Rules, Regulations, Bye-laws of the Stock Exchange, Mumbai, SEBI Act or any other laws in force from time to time.

BSE Ltd. is not answerable, responsible or liable for any information on this Website or for any services rendered by our employees, our servants, and us.

Personal Loan, Fixed Deposit, EMI Card are provided by Bajaj Finance Limited. Bajaj Financial Securities Limited is only a distributor. These are not exchange traded products and all disputes with respect to the distribution activity, would not have access to exchange investor redressal forum or Arbitration mechanism.

No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.

Please Note:

  1. Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020

  2. Update your mobile number & email ID with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.

  3. Pay 20% upfront margin of the transaction value to trade in cash market segment.

  4. Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 and BSE vide notice no. 20200731-7 dated July 31, 2020 and 20200831-45 dated August 31, 2020 and other guidelines issued from time to time in this regard.

  5. Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.

Client Registration Documents (Rights & Obligations, Risk Disclosure Document, Do's & Don'ts) in Vernacular Language: BSE | NSE

If the client wishes to revoke /cancel the EDIS mandate placed by them, they can write on email to connect@bajajbroking.in  or call on the toll free number.

Advisory for Investors : NSE | BSE

We also do pro-account trading in Equity & Derivatives Segment.

Filling complaints on SCORES - Easy & Quick

A.  Register on SCORES portal B. Mandatory details for filling complaints on SCORES (i) Name, PAN, Address, Mobile Number, E-mail ID C. Benefits: (i) Effective Communication (ii) Speedy redressal of the grievances.

SEBI Registration No.: INZ000218931 | BSE Cash/CDS/F&O (Member ID: 6706) | NSE Cash/F&O/CDS (Member ID: 90177) | DP registration No : IN-DP-418-2019 | CDSL DP No.: 12088600 | NSDL DP No. IN304300 | AMFI Registration No.: ARN – 163403 Research Analyst SEBI Registration No. INH000010043

Compliance officer:

Mr. Boudhayan Ghosh 
TEL: 020-48574486
Email: compliance_sec@bajajbroking.in, for any investor grievances write to compliance_sec@bajajbroking.in for DP related to Compliance_dp@bajajbroking.in .

DISCLAIMER

STANDARD DISCLAIMER

Investments in the securities market are subject to market risk, read all related documents carefully before investing.

Reg Office: Bajaj Auto Limited Complex, Mumbai –Pune Road Akurdi Pune 411035. Corporate Office: Bajaj Financial Securities Limited, 1st Floor, Mantri IT Park, Tower B, Unit No 9 & 10, Viman Nagar, Pune, Maharashtra 411014. SEBI Registration No.: INZ000218931 | BSE Cash/F&O/CDS (Member ID:6706) | NSE Cash/F&O/CDS (Member ID: 90177) | DP registration No: IN-DP-418-2019 | CDSL DP No.: 12088600 | NSDL DP No. IN304300 | AMFI Registration No.: ARN –163403. 

Website: Bajaj Broking

RESEARCH DISCLAIMER

Broking services offered by Bajaj Financial Securities Limited | Registered Office: Bajaj Auto Limited Complex , Mumbai –Pune Road Akurdi Pune 411035 | Corporate Office: Bajaj Financial Securities Limited, 1st Floor, Mantri IT Park, Tower B, Unit No 9 & 10, Viman Nagar, Pune, Maharashtra 411014 | CIN: U67120PN2010PLC136026 | Research Analyst SEB I Registration No: INH000010043.

Details of Compliance Officer: 

Mr. Boudhayan Ghosh (For Broking/DP/Research)
Email: compliance_sec@bajajbroking.in
Contact No.: 020-4857 4486 

Investment in the securities involves risks, investor should consult his own advisors/consultant to determine the merits and risks of investment.

DISCLOSURES

Disclosures under the provisions of SEBI (Research Analysts) Regulations 2014 (Regulations) 

Bajaj Financial Securities Limited ("Bajaj Broking" or "Research Entity") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services and related activities. There were no instances of non-compliance by Bajaj Financial Securities Limited on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years. This research report has been prepared and distributed byBajaj Financial Securities Limited in the capacity of a Research Analyst as per Regulation 22(1) of SEBI (Research Analysts) Regulations 2014 having SEBI Registration No. INH000010043. 

DISCLAIMER

This e-mail/ short message service (SMS) may contain confidential, proprietary or legally privileged information. It should not be used by anyone who is not the original intended recipient. If you have erroneously received this message, please delete it immediately and notify the sender. The recipient acknowledges thatBajaj Financial Securities Limited or its holding and/or associated companies, as the case may be, are unable to exercise control or ensure or guarantee the integrity of/over the contents of the information contained in e-mail /SMS transmissions and further acknowledges that any views expressed in this message are those of the individual sender and no binding nature of the message shall be implied or assumed unless the sender does so expressly with due authority of Bajaj Financial Securities Limited. This message is not intended as an offer or publication or solicitation for distribution for subscription of or purchase or sale of any securities or financial instrument(s) to anyone in whose jurisdiction such subscription etc. requires prior local regulatory clearance or is contrary to the local laws of the land in any manner or as an official confirmation of any transaction. Before opening any attachments, please check them for viruses and defects. 

This service / information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose unless otherwise expressly authorised. This service / information is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subjectBajaj Financial Securities Limited and affiliates/ group/holding companies to any registration or licensing requirements within such jurisdiction. The distribution of this document in certain jurisdictions may be restricted by law, and persons in whose possession this document comes, should inform themselves about and observe any such restrictions.  

The data would be provided to the clients on an "as is" and "where-is" basis, without any warranty. Bajaj Financial Securities Limited or its subsidiaries and associated companies shall not be liable for any delay or any other interruption which may occur in providing the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of the Bajaj Financial Securities Limited or its subsidiaries and associated companies to provide the data. In no event shall the Bajaj Financial Securities Limited or its holding and associated companies be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data provided by the Bajaj Financial Securities Limited or its holding and associated companies.

ADDITIONAL DISCLAIMER FOR U.S. PERSONS

Bajaj Financial Securities Limited is not a registered broker-dealer under the U.S. Securities Exchange Act of 1934, as amended (the"1934 act") and under applicable state laws in the United States. In addition, Bajaj Financial Securities Limited is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by Bajaj Financial Securities Limited, including the products and services described herein are not available to or intended for U.S. persons. This email message does not constitute an offer or invitation to purchase or subscribe for any securities or solicitation of any investments or investment services and/or shall not be considered as an advertisement tool. "U.S. Persons" are generally defined as a natural person, residing in the United States or any entity organized or incorporated under the laws of the United States. US Citizens living abroad may also be deemed "US Persons" under certain rules.  

ADDITIONAL DISCLAIMER FOR CANADIAN PERSONS

Bajaj Financial Securities Limited is not a registered adviser or dealer under applicable Canadian securities laws nor has it obtained an exemption from the adviser and/or dealer registration requirements under such law. Accordingly, any brokerage and investment services provided by Bajaj Financial Securities Limited, including the products and services described herein are not available to or intended for Canadian persons.  

This mailer and its respective contents do not constitute an offer or invitation to purchase or subscribe for any securities or solicitation of any investments or investment services.  

DISCLAIMER FOR REPORT

DISCLOSURES UNDER THE PROVISIONS OF SEBI (RESEARCH ANALYSTS) REGULATIONS 2014 (REGULATIONS)

Bajaj Financial Securities Limited ("Bajaj Broking" or "Research Entity") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services and related activities.  

This Report has been prepared by Bajaj Financial Securities Limited in the capacity of a Research Analyst having SEBI Registration No. INH000010043 and distributed as per SEBI (Research Analysts) Regulations 2014. This report does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. The information contained herein is from publicly available data or other sources believed to be reliable. This report is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this report should make such investigation as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult his own advisors to determine the merits and risks of such investment. The investment discussed or views expressed may not be suitable for all investors.  

This information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Bajaj Financial Securities Limited and associates / group companies to any registration or licensing requirements within such jurisdiction. The distribution of this report in certain jurisdictions may be restricted by law, and persons in whose possession this report comes, should observe, any such restrictions. The information given in this report is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This information is subject to change without any prior notice. Bajaj Financial Securities Limited reserves the right to make modifications and alterations to this statement as may be required from time to time. Bajaj Financial Securities Limited or any of its associates / group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. Bajaj Financial Securities Limited is committed to providing independent and transparent recommendation to its clients. Neither Bajaj Financial Securities Limited nor any of its associates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including loss of revenue or lost profits that may arise from or in connection with the use of the information. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein. Past performance is not necessarily a guide to future performance .The disclosures of interest statements incorporated in this report are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. The information provided in these reports remains, unless otherwise stated, the copyright of Bajaj Financial Securities Limited. All layout, design, original artwork, concepts and other Intellectual Properties, remains the property and copyright of Bajaj Financial Securities Limited and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the copyright holders.  

We offer our research services to clients as well as our prospects. Though this report is disseminated to all the customers simultaneously, not all customers may receive this report at the same time. We will not treat recipients as customers by virtue of their receiving this report.  

Bajaj Financial Securities Limited and its associates, officer, directors, and employees, research analyst (including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company(ies), mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company/company(ies) discussed herein or act as advisor or lender/borrower to such company(ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance. Bajaj Financial Securities Limited may have proprietary long/short position in the above-mentioned scrip(s) and therefore should be considered as interested. The views provided herein are general in nature and do not consider risk appetite or investment objective of any particular investor; readers are requested to take independent professional advice before investing. This should not be construed as invitation or solicitation to do business with Bajaj Financial Securities Limited.  

Bajaj Financial Securities Limited or its associates may have received compensation from the subject company in the past 12 months. Bajaj Financial Securities Limited or its associates may have managed or co-managed public offering of securities for the subject company in the past 12 months. Bajaj Financial Securities Limited or its associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. Bajaj Financial Securities Limited or its associates may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. Bajaj Financial Securities Limited or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Research analyst or his/her relative or Bajaj Financial Securities Limited’s associates may have financial interest in the subject company. Bajaj Financial Securities Limited, its associates, research analyst and his/her relative may have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance.  

Research analyst has served as an officer, director or employee of subject Company: No  

Bajaj Financial Securities Limited has financial interest in the subject companies: No  

Bajaj Financial Securities Limited’s Associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report.  

Research analyst or his/her relative has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No  

Bajaj Financial Securities Limited has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No  

Subject company may have been client during twelve months preceding the date of distribution of the research report.  

There were no instances of non-compliance by Bajaj Financial Securities Limited on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years. A graph of daily closing prices of the securities is also available at NSE

ANALYST CERTIFICATION

The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.  

RISK DISCLOSURE ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

BROKERAGE DISCLAIMER

All leveraged intraday positions will be squared off on the same day. There is no restriction on the withdrawal of the unutilised margin amount. Brokerage will not exceed the SEBI prescribed limit. Visit : Pricing

MTF 

As subject to the provisions of SEBI Circular CIR/MRD/DP/54/2017 dated June 13, 2017, and the terms and conditions mentioned in the lights and obligations statement issued by the TM (if applicable).  

US INVESTING

International investment is not supervised by any regulatory body in India. Thus, any claim or dispute relating to such investment or enforcement of any agreement/contract /claim will not be under laws and regulations of the recognized stock exchanges and investor protection under Indian Securities Law. The account opening process will be carried out on Vested platform and Bajaj Financial Securities Limited will not have any role in it.  

IPO 

This should not be construed as soliciting investment. Investors’ discretion is required. Kindly consult your financial expert before investing. No need to issue cheques by investors while subscribing to IPO. Investments in securities markets are subject to market risks, read all the related documents carefully before investing.  

SCREENERS 

Screeners is not Exchange-approved products and any disputes related to the same will not be dealt on the Exchange platform. 

SECURITIES 

Securities quoted are exemplary and not recommendatory. 

IPV 

Account would be open after all procedure relating to IPV and client due diligence is completed. 

IMAGES 

The images used are only for representation purpose. Proper due diligence has been done for the images and the image is not of any artist. The same is captured from royalty free sites.

THIRD PARTY PRODUCT DISCLAIMER

Bajaj Financial Securities Limited is a distributor for Non-Broking Products/Services such as Mutual Funds, Mutual Funds SIP, IPO, Bonds, Insurance, PMS, Global Investing, any other third-party products/services. These are not Exchange Traded Products, and we are only acting as distributors. All disputes with respect to the distribution activity, would not have access to SCORES/ODR, Exchange investor redressal forum or Arbitration mechanism. Please refer to the detailed disclaimer for Third-Party Products.

DISCLOSURE TO CLIENTS REGARDING PAYOUT OF FUNDS

As per SEBI circular no. SEBI/HO/MIRSD/MIRSD-PoD-1/P/CIR/2023/84 dated June 08, 2023, Stockbrokers are required to upstream the entire client funds lying with them to the Clearing Corporation. Based on client’s request the funds’ release request must be placed with the Clearing Corporation. Based on the internal process and cut-off timelines of the Clearing Corporation the funds will be released to the Stock Broker. In view of this new process, as specified by the regulatory and the cut-off time of Clearing Corporation/Banks processing the funds, Bajaj Financial Securities Limited cannot commit the exact time for releasing funds payout to its client. Clients are requested to note that, Bajaj Financial Securities Limited will not be responsible for any inconvenience caused to clients due to delay in release of funds payout, including fines, delayed charges, defaults, etc.